Patient global assessment (PGA) is included in almost all rheumatoid arthritis (RA) composite disease activity indices and definitions of remission. However, different PGA formulations exist and are used interchangeably in research and clinical practice. We investigated how five different PGA formulations used in four disease indices affect the remission rates. This was an ancillary analysis of data from a cross-sectional study in patients with RA. The data comprised the following: 28-joint counts, C-reactive protein, and five PGA formulations. Remission rate variation was assessed using five PGA formulations in each index (ACR/EULAR Boolean, CDAI, SDAI, and DAS28-CRP). PGA agreement was assessed by the following: Pearson's correlation; Bland-Altman plots; paired samples t test; and establishing the proportion of patients who scored (i) all formulations within an interval of 20 mm and (ii) each formulation ≤ 10 mm. This analysis included 191 patients. PGA formulations presented good correlations (≥ 0.65), but Bland-Altman plots showed clinically significant differences, which were statistically confirmed by comparison of means. Just over a half (51.8%) of patients scored all PGA formulations within a 20-mm interval. The proportion of those scoring ≤ 10 mm varied from 11.5 to 16.2%. When different formulations of PGA were used in each index, remission differences of up to 4.7, 4.7, 6.3, and 5.2% were observed. When formulations were used in their respective indices, as validated, the remission rates were similar (13.1, 13.6, 14.1, and 18.3%). Using PGA formulations interchangeably may have implications in the assessment of disease activity and in the attainment of remission, and this can impact upon management decisions.
Introduction
In the last two decades, significant advances have been observed in the treatment of rheumatoid arthritis (RA) as a result not only of the introduction of new therapies but also of new strategies, such as Btreat-to-target^(T2T) [1] . Remission or at least low disease activity (LDA) has become a consensual guiding target for therapy [2] [3] [4] , as this provides the best assurance of good structural and functional outcomes [5] . Thus, the assessment of disease activity is crucial, and the use of combined indices and their cut-offs is recommended to guide and evaluate treatment options, both in research and in clinical practice [2] [3] [4] .
However, a Bgold standard^definition of remission has not been established [2] . The four commonly used definitions are as follows: Disease Activity Score 28 (DAS28)-based remission [4, 6] , the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean-based remission, the Clinical Disease Activity Index (CDAI)-based remission, and the Simplified Disease Activity Index (SDAI)-based remission; the last two have been elected as preferential [2, 3] . Not surprisingly, different criteria provide different rates of remission [7] .
Patient global assessment (PGA) is the only patientreported outcome (PRO) included in all of the abovementioned disease activity indices, and considerable attention has been paid recently to its influence on remission rates [8] [9] [10] . Several limitations have been pointed out to this assessment, including variations in the (i) phrasing of the question (e.g., Bdisease,^Barthritis,^or Bhealth^), (ii) phrasing of the anchors (e.g., Bvery well^or Bthe best^), (iii) type of rating scale (e.g., visual analogue scale (VAS) with 10 cm or numeric rating scale (NRS) from 0 to 10), and (iv) time intervals to which the evaluation refers (e.g., Blast week^or Btoday^) [10, 11] . Despite these observations, the different formulations of PGA seem to be used indistinctly in both clinical practice and in research [10] .
This study aimed at (i) evaluating if and how the score of PGA by patients with RA differs according to the formulation of the question and (ii) assessing the influence of this variability upon remission and LDA rates obtained with four different indices.
Participants and methods

Study design and setting
This was an ancillary analysis of data from an observational, cross-sectional study, performed in a single rheumatology outpatient department [9] .
Participants
The original study included consecutive adult patients with a definite diagnosis of RA (ACR 1987 revised criteria or ACR/EULAR 2010 classification criteria). Patients were excluded if they declined participation or if they were unable to respond to the questionnaires unaided. Ethical approval was granted by the Ethics Committee of the Faculty of Medicine, University of Coimbra (CE-037/2015). All patients signed consent according to the Declaration of Helsinki. Additional consent for this ancillary study was not required. Here, data was included from patients who had completed the five versions of PGA and had information for all disease activity indices. All formulations were presented as a 0-100-mm, unmarked, horizontal VAS, with their respective anchors.
Patient global assessment
Other variables
Questionnaires included patient demographic data and other PROs, as described elsewhere [9] . The attending physician provided the following: tender 28-joint count (TJC28), swollen 28-joint count (SJC28), C-reactive protein (CRP), and Physician Global Assessment (PhGA).
Each formulation of PGA was presented in a single page of the questionnaire, interspersed with other PROs to serve as Bdistractors^ [11] , and these were completed before clinical consultations.
Disease activity indices
The following disease activity indices and respective cut-off points were used to assess remission: (i) ACR/EULAR Boolean-based definition of remission: TJC28, SJC28, CRP (in mg/dl), and PGA (in cm) all ≤ 1 [2] , (ii) SDAI ≤ 3.3 [12] , (iii) CDAI ≤ 2.8 [12] , and (iv) DAS28-CRP < 1.9 [6] . Cut-offs for LDA state were as follows: SDAI ≤ 11 [12] , CDAI ≤ 10 [12] , and DAS28-CRP ≤ 3.1 [6] .
Statistical methods
Differences across the five PGA formulations were assessed by the following: (i) Pearson's correlation coefficients; (ii) Bland-Altman plots (with limits of agreement of 1.96 × SD mean difference ) [14] , using the ACR/EULAR formulation (v1) as the reference (defined a priori, based on results of a systematic review [10] ); (iii) paired samples t test, comparing the mean scores obtained with each formulation, (v1 used as reference); (iv) examining the proportion of patients who scored all PGA formulations within an interval of 20 mm; (v) comparing the proportion of patients who scored each formulation ≤ 10 mm; and (vi) comparing the proportion of patients classified as in remission (and in LDA) according to each formulation; chi-square test was used to test this difference, namely using indices with their assigned PGA formulation.
Results
Patient characteristics
A total of 191 patients were included in this analysis. The demographic and clinical characteristics are presented in Supplementary Table S1 . Eighty-three percent of the participants were female, with mean (SD) age 59 (13) years, disease duration 12 (9) years, and DAS28-CRP3v 2.5 (1.0). Thirtyfour percent were on biologic disease-modifying antirheumatic drugs (bDMARDs).
Differences between PGA formulations
The correlations between PGA formulations were all good, varying from r p = 0.65 to r p = 0.80 (all p < 0.001) (Supplementary Table S2 ).
The Bland-Altman plots showed low agreement between formulations, with 95% limits of variability ranging from [− 37.8 to + 30.4 mm (v2 vs v1)] to [− 49.7 to + 40.9 mm (v5 vs v1)] (Supplementary Fig. S1 ).
When comparing mean scores, the two DAS28 formulations obtained the lowest average scores (42.9 and 42.3 mm, respectively). In contrast, the formulations created by the investigators and the SDAI/CDAI resulted in the highest mean scores (48.1 and 47.2 mm, respectively), presenting a statistically significant difference (p = 0.0003 and p = 0.006, respectively) when compared with the reference (Table 1) .
Ninety-nine patients (51.8%) responded to all five formulations within an interval of 20 mm. The ACR/EULAR formulation had the largest number of patients scoring ≤ 10 mm (16.2%), while the investigator's and the SDAI/CDAI formulations presented the lowest proportions (11.5 and 12.0%, respectively) ( Table 1) .
Differences in remission rates according to PGA formulations
When the proper formulations were used in their respective indices, the remission rates were similar in three disease activity indices: 13.1, 13.6, and 14.1%, respectively, for ACR/ EULAR Boolean criteria (using v1), CDAI (using v2), and SDAI (using v2). The percentage of patients classified in remission with the DAS28-CRP (using v4) was slightly higher (18.3%) (Fig. 1) . Chi-square test revealed statistically significant differences across all these proportions (Table 2) .
When assessing the use of the different formulations in different indices, we observed that the ACR/EULAR formulation was associated with the highest rate of remission in all the four indices. Conversely, the SDAI/CDAI and the investigator's formulations were associated with the lowest remission rates. The maximum differences in rates of remission with the same index depending on the PGA formulation used (highest minus lowest) were as follows: 4.7% (ACR/EULAR Boolean-based), 4.7% (SDAI), 6.3% (CDAI), and 5.2% (DAS28-CRP) (Fig. 1) . Considering the patients that reached at least LDA, the maximum differences between formulations ranged from 2.6 to 4.8% according to the index used (Table 3 ).
Discussion
This study tested how the PGA scored by individual patients with RA varies according to five different formulations of this question. We assessed the impact of these formulations upon the rates of remission and LDA defined by different disease indices. These issues have a direct impact upon treatment decisions, according to current recommendations. Although the Pearson's correlations among these formulations were good, the comparison of PGA mean values showed statistically significant differences. The 95% limits of variability revealed by the Bland-Altman plots would probably be considered as relevant by most practicing clinicians. Only approximately half of patients (51.8%) scored the five PGAs within a 20-mm interval. More importantly, differences in remission rates using different formulations of PGA for the same index were significant: for instance, ACR/EULAR Boolean-based remission varied between 8.4 and 13.1% only by switching between the five versions of PGA; this difference was highest using CDAI, with remission rates varying 13.6 and 19.9%.
Even though PGA has been widely employed in RA research [10] , only few studies [11, [15] [16] [17] have examined the effect of using different formulations in the assessment of disease activity status. The main conclusions have been, Paired samples t test using, as pre-defined, the ACR/EULAR formulation as reference Fig. 1 Remission rates according to four disease activity indices using five different formulations of patient global assessment (n = 191). The arrows represent the remission rate measured by a disease activity index with its respective PGA formulation largely, similar in three of these studies [15] [16] [17] : although the formulations Bare individually not equivalent, they may be used interchangeably for calculating composite indices [ 17] . French et al. [11] suggested caution on this interchangeable use of formulations and advocated standardization of PGA. The above studies tested two [16, 17] , three [15] , or five [11] PGA formulations that resulted in maximum discrepancies in the remission rates of 0.5% [17] , 0.9% [15] , 1.3% [16] , and 4.0% [11] using DAS28; 1.0% using CDAI [17] ; and 0.4% using Routine Assessment of Patient Index Data 3 (RAPID3) [17] . Our study presented higher percentages of variation between formulations: 5.2% for DAS28 and 6.3% for CDAI. The main characteristics and results of the previous and present study are summarized in Supplementary Table S3 .
The above-mentioned discrepancy between individual study results may be related to different factors, with Figures in italic represent the discordant classification between disease activity indices ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; DA, disease activity; DAS28-CRP, disease activity score 28-joint count using C-reactive protein; EULAR, European League Against Rheumatism; GH, global health; PGA, patient global assessment; SDAI, Simplified Disease Activity Index a Fleishman's et al. [6] cut-off: remission < 1.9 emphasis on the phrasing of the formulations. In our study, asking B(...) how do you feel your arthritis is today?^(as in ACR/EULAR) led to the highest percentage of remission. However, using a very similar formulation (as in SDAI/CDAI), but without a reference period, the opposite effect was observed. In a qualitative study from our group [18] , many patients preferred being asked Btoday^instead of Blast week^because it is easier to recall the symptoms and scoring them. It was rather surprising that the PGA formulation created by the investigators, using a more detailed and culturally adapted explanation was the one with the highest mean value and with fewer patients scoring ≤ 10 mm. A possible explanation was the inclusion of Bfatigue,^which patients might not otherwise consider a manifestation of RA [8] . Secondly, when using the DAS28, the effect of different PGA formulations is negligible, mostly because of the limited weight that is given to this component [16] . Finally, the levels of disease activity of the samples (influenced by the study design, among other factors) may have influenced the discrepancies, as higher levels of disease activity may be expected to be associated with larger differences between PGA formulations [16] . Our results, however, contradict this assumption given that our sample presented near half levels of disease activity but much higher discrepancies compared with previous studies (Supplementary Table S3 ). This suggests that culture and educational levels may play an important role in these assessments, and these influences should not be ignored [19] . One possible limitation of this study is the use of VAS instead of NRS in the SDAI/CDAI formulation. Use of VAS (rather than NRS) helped to standardize measures, and evidence from previous studies [19, 20] suggest that this would not change our conclusions. Another limitation was the presentation of formulations in the same sequence to all patients, although they were interspersed with other scales.
One important strength of our study was the use of four disease activity indices and four commonly used PGA formulations. This was also the first study to access the influence of the proper PGA formulations in the respective indices. This study used the updated cut-offs for the DAS28-CRP [6] , which allowed a better comparison between the indices. Finnaly, recruiting patients from clinical practice rather than using data from a clinical trial was another advantage, as PGA instructions and interpretation by patients may be different in both contexts.
Although the added value of including PGA in the definition of disease activity remission is being debated [21, 22] , it seem unequivocal, in face of our results, that each formulation of PGA should be limited to the respective disease activity index or perhaps ideally that the PGA formulation should be standardized into a unique format.
